Sort
10,766 grants matching “checkpoint inhibitor”
ATM Controls Genomic Stability in Pluripotent Stem Cells
$33,428Jason Mark Beckta · Virginia Commonwealth University · F30 · FY2012 · CA
Molecular engineering and systematic evaluation of bispecific aptamers to develop potent and efficacious therapies for the immunomodulation of Non-Small Cell Lung Cancer
$33,378Brian J Thomas · University Of Missouri-Columbia · F30 · FY2023 · CA
Delineating the role of calcineurin in modulating the immune response in acute lymphoblastic leukemia
$33,318Alisha Desiree Hunter · Emory University · F31 · FY2022 · CA
Mechanisms underlying therapy failure of immune checkpoint inhibitors and Notch1 loss-mediated immunosuppression in head and neck cancers
$33,288Rachel A Woolaver · University Of Colorado Denver · F31 · FY2018 · DE
The Role of Vascular Endothelial Glutaminase in Tumor Vessel Normalization and Response to Therapy
$33,247Verra Ngwa · Vanderbilt University · F31 · FY2021 · CA
Identifying Genetic Drivers of the Immunosuppressive Tumor Microenvironment in Lung Cancer
$33,187Gurkan Mollaoglu · University Of Utah · F99 · FY2017 · CA
The Role of 53BP1 Interacting Proteins in Regulation of DNA Repair Choice
$33,167Jinesh Shailesh Gheeya · Rbhs -Cancer Institute Of New Jersey · F30 · FY2015 · CA
The Role of 53BP1 Interacting Proteins in Regulation of DNA Repair Choice
$33,166Jinesh Shailesh Gheeya · Rbhs -Cancer Institute Of New Jersey · F30 · FY2014 · CA
Ras18-mediated Fanconi Anemia pathway activation in response to camptothecin
$33,078Komaraiah Palle · Univ Of North Carolina Chapel Hill · R01 · FY2012 · GM
The Role of Tumor-Targeted TLR5 Activation in Reversing Immune Checkpoint Therapy Resistance
$33,025Sarah E Glazer · University Of Tx Md Anderson Can Ctr · F30 · FY2020 · CA
The Study of Immune Effects in Gliomas Treated with Oncolytic Viruses in Combination with IDO Inhibitors
$33,010Teresa T Nguyen · University Of Tx Md Anderson Can Ctr · F31 · FY2020 · CA
Lymphoma & Leukemia Research Program (Project-007)
$32,997Ronald Levy · Stanford University · P30 · FY2017 · CA
Enhancing triple negative breast cancer response to immune checkpoint inhibitor therapy via targeted therapies
$32,986Kennady Bullock · Vanderbilt University · F31 · FY2023 · CA
Mechanisms underlying therapy failure of immune checkpoint inhibitors and Notch1 loss-mediated immunosuppression in head and neck cancers
$32,919Rachel A Woolaver · University Of Colorado Denver · F31 · FY2020 · DE
Cancer-associated fibroblasts promote thyroid cancer malignancy through Wnt signaling
$32,884Matthew A Loberg · Vanderbilt University · F30 · FY2023 · CA
Molecular indicators of treatment responses and adverse events in melanoma
$32,820Sarah Martinez Roth · Georgetown University · F31 · FY2020 · CA
Impact of local and systemic cellular senescence toward Triple Negative Breast Cancer growth and drug therapy
$32,820Irfan Khan · Georgetown University · F30 · FY2020 · CA
The Role of 53BP1 Interacting Proteins in Regulation of DNA Repair Choice
$32,722Jinesh Shailesh Gheeya · Rbhs -Cancer Institute Of New Jersey · F30 · FY2013 · CA
The Role of Glutamine Metabolism in Monocyte-Derived Dendritic Cell Differentiation in the Soft-Tissue Sarcoma Microenvironment
$32,650Graham Lobel · University Of Pennsylvania · F30 · FY2024 · CA
Ferroptosis as a Modulator of Checkpoint Inhibitor Immunotherapy
$32,549Ronan Christopher Talty · Yale University · F30 · FY2023 · CA
The Role of Mutant p53 in Regulating T-cell Immune Evasion in Pancreatic Adenocarcinoma and Other Cancers
$32,521Deborah Ann Silverman · University Of Tx Md Anderson Can Ctr · F30 · FY2019 · CA
Examining the impact of laboratory housing temperature on murine CD28 and the response to anti-PD-1
$32,512Caitlin M James · Roswell Park Cancer Institute Corp · F31 · FY2023 · CA
The Study of Immune Effects in Gliomas Treated with Oncolytic Viruses in Combination with IDO Inhibitors
$32,506Teresa T Nguyen · University Of Tx Md Anderson Can Ctr · F31 · FY2019 · CA
Polyamines drive glioblastoma progression
$32,475Kristen Kay · Cleveland Clinic Lerner Com-Cwru · F31 · FY2023 · CA
Developing Imaging Biomarkers of Oral Squamous Cell Carcinoma Response to Immunotherapy
$32,412Celia Dejohn · Roswell Park Cancer Institute Corp · F31 · FY2022 · DE